KR20230120138A - Myc 발현을 조절하기 위한 조성물 및 방법 - Google Patents
Myc 발현을 조절하기 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20230120138A KR20230120138A KR1020237024060A KR20237024060A KR20230120138A KR 20230120138 A KR20230120138 A KR 20230120138A KR 1020237024060 A KR1020237024060 A KR 1020237024060A KR 20237024060 A KR20237024060 A KR 20237024060A KR 20230120138 A KR20230120138 A KR 20230120138A
- Authority
- KR
- South Korea
- Prior art keywords
- expression
- repressor
- sequence
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 940
- 238000000034 method Methods 0.000 title claims abstract description 357
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 title claims abstract description 263
- 102100038895 Myc proto-oncogene protein Human genes 0.000 title claims abstract description 262
- 239000000203 mixture Substances 0.000 title abstract description 27
- 239000012636 effector Substances 0.000 claims abstract description 391
- 230000008685 targeting Effects 0.000 claims abstract description 301
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 122
- 201000011510 cancer Diseases 0.000 claims abstract description 84
- 108020004414 DNA Proteins 0.000 claims abstract description 57
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 338
- 102000039446 nucleic acids Human genes 0.000 claims description 317
- 108020004707 nucleic acids Proteins 0.000 claims description 317
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 118
- 239000002773 nucleotide Substances 0.000 claims description 118
- 125000003729 nucleotide group Chemical group 0.000 claims description 118
- 230000027455 binding Effects 0.000 claims description 104
- 239000011701 zinc Substances 0.000 claims description 77
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 71
- 230000035899 viability Effects 0.000 claims description 71
- 229910052725 zinc Inorganic materials 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 68
- 230000002829 reductive effect Effects 0.000 claims description 61
- -1 system Proteins 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 36
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 32
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 29
- 229940124597 therapeutic agent Drugs 0.000 claims description 28
- 230000005764 inhibitory process Effects 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 230000001629 suppression Effects 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 23
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 22
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 22
- 108060004795 Methyltransferase Proteins 0.000 claims description 22
- 102000016397 Methyltransferase Human genes 0.000 claims description 22
- 229960003787 sorafenib Drugs 0.000 claims description 22
- 230000004614 tumor growth Effects 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 17
- 229940125763 bromodomain inhibitor Drugs 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 13
- 239000011541 reaction mixture Substances 0.000 claims description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 229940043355 kinase inhibitor Drugs 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004066 trametinib Drugs 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 claims description 6
- 229940124647 MEK inhibitor Drugs 0.000 claims description 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 6
- 238000003570 cell viability assay Methods 0.000 claims description 6
- 201000004098 fibrolamellar carcinoma Diseases 0.000 claims description 6
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 230000002018 overexpression Effects 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 238000011521 systemic chemotherapy Methods 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 abstract description 66
- 101150039798 MYC gene Proteins 0.000 abstract description 53
- 230000035897 transcription Effects 0.000 abstract description 10
- 238000013518 transcription Methods 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 263
- 108090000623 proteins and genes Proteins 0.000 description 193
- 230000000694 effects Effects 0.000 description 84
- 108090000765 processed proteins & peptides Proteins 0.000 description 78
- 108091028043 Nucleic acid sequence Proteins 0.000 description 67
- 108020004999 messenger RNA Proteins 0.000 description 67
- 102000004169 proteins and genes Human genes 0.000 description 61
- 235000018102 proteins Nutrition 0.000 description 56
- 102000004196 processed proteins & peptides Human genes 0.000 description 52
- 229920001184 polypeptide Polymers 0.000 description 51
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 50
- 238000010453 CRISPR/Cas method Methods 0.000 description 47
- 102000011252 Krueppel-associated box Human genes 0.000 description 41
- 108050001491 Krueppel-associated box Proteins 0.000 description 41
- 108700009124 Transcription Initiation Site Proteins 0.000 description 40
- 230000009467 reduction Effects 0.000 description 40
- 150000002632 lipids Chemical class 0.000 description 33
- 102100025169 Max-binding protein MNT Human genes 0.000 description 32
- 108091006107 transcriptional repressors Proteins 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 230000001404 mediated effect Effects 0.000 description 31
- 230000001105 regulatory effect Effects 0.000 description 31
- 108020005004 Guide RNA Proteins 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 26
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 239000002105 nanoparticle Substances 0.000 description 23
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 21
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 21
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 21
- 230000003828 downregulation Effects 0.000 description 20
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 19
- 230000003833 cell viability Effects 0.000 description 19
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 18
- 230000004927 fusion Effects 0.000 description 18
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 description 16
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 description 16
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 description 16
- 101000613960 Homo sapiens Lysine-specific histone demethylase 1B Proteins 0.000 description 16
- 102100040596 Lysine-specific histone demethylase 1B Human genes 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 150000003384 small molecules Chemical class 0.000 description 14
- 102000003964 Histone deacetylase Human genes 0.000 description 13
- 108090000353 Histone deacetylase Proteins 0.000 description 13
- 102000055027 Protein Methyltransferases Human genes 0.000 description 13
- 108700040121 Protein Methyltransferases Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000004049 epigenetic modification Effects 0.000 description 13
- 208000019423 liver disease Diseases 0.000 description 13
- 102000002488 Nucleoplasmin Human genes 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 229940127089 cytotoxic agent Drugs 0.000 description 12
- 108060005597 nucleoplasmin Proteins 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 11
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 11
- 101710160287 Heterochromatin protein 1 Proteins 0.000 description 11
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 11
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 11
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 description 11
- 101000931374 Homo sapiens Zinc finger protein ZFPM1 Proteins 0.000 description 11
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 11
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 11
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 11
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 description 11
- 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 11
- 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 11
- 102100020993 Zinc finger protein ZFPM1 Human genes 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 11
- 230000001973 epigenetic effect Effects 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 11
- VSDFDVBYONIJLD-UHFFFAOYSA-N 3-[(4-chlorophenyl)methoxy]-2-[4-chloro-3-(trifluoromethyl)phenyl]-6-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]phenol Chemical group CN1N=C(C=C1C1=C(O)C(=C(OCC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(Cl)C(=C1)C(F)(F)F)C(F)(F)F VSDFDVBYONIJLD-UHFFFAOYSA-N 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 10
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 description 10
- 108010074870 Histone Demethylases Proteins 0.000 description 10
- 102000008157 Histone Demethylases Human genes 0.000 description 10
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000012384 transportation and delivery Methods 0.000 description 10
- 108091005772 HDAC11 Proteins 0.000 description 9
- 102000011787 Histone Methyltransferases Human genes 0.000 description 9
- 108010036115 Histone Methyltransferases Proteins 0.000 description 9
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 9
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 9
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 9
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 9
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 9
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 9
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 9
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 9
- 108010033040 Histones Proteins 0.000 description 9
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 9
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 9
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 9
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 9
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 9
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 9
- 101001032113 Homo sapiens Histone deacetylase 7 Proteins 0.000 description 9
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 9
- 101001032092 Homo sapiens Histone deacetylase 9 Proteins 0.000 description 9
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 9
- 101000709248 Homo sapiens NAD-dependent protein deacetylase sirtuin-7 Proteins 0.000 description 9
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 description 9
- 101000863629 Homo sapiens NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Proteins 0.000 description 9
- 101001035694 Homo sapiens Polyamine deacetylase HDAC10 Proteins 0.000 description 9
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 9
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 9
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 9
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 9
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 9
- 102100034376 NAD-dependent protein deacetylase sirtuin-7 Human genes 0.000 description 9
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 description 9
- 102100030709 NAD-dependent protein lipoamidase sirtuin-4, mitochondrial Human genes 0.000 description 9
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 9
- 108010041191 Sirtuin 1 Proteins 0.000 description 9
- 108010041216 Sirtuin 2 Proteins 0.000 description 9
- 230000032823 cell division Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 101000619676 Drosophila melanogaster Lipid storage droplets surface-binding protein 2 Proteins 0.000 description 8
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 8
- 102100027770 Histone-lysine N-methyltransferase KMT5B Human genes 0.000 description 8
- 102100027788 Histone-lysine N-methyltransferase KMT5C Human genes 0.000 description 8
- 102100023696 Histone-lysine N-methyltransferase SETDB1 Human genes 0.000 description 8
- 102100023676 Histone-lysine N-methyltransferase SETDB2 Human genes 0.000 description 8
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 description 8
- 102100028988 Histone-lysine N-methyltransferase SUV39H2 Human genes 0.000 description 8
- 101000877314 Homo sapiens Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 8
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 description 8
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 8
- 101001008821 Homo sapiens Histone-lysine N-methyltransferase KMT5B Proteins 0.000 description 8
- 101001008824 Homo sapiens Histone-lysine N-methyltransferase KMT5C Proteins 0.000 description 8
- 101000684609 Homo sapiens Histone-lysine N-methyltransferase SETDB1 Proteins 0.000 description 8
- 101000684615 Homo sapiens Histone-lysine N-methyltransferase SETDB2 Proteins 0.000 description 8
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 description 8
- 101000696699 Homo sapiens Histone-lysine N-methyltransferase SUV39H2 Proteins 0.000 description 8
- 101000613958 Homo sapiens Lysine-specific demethylase 2A Proteins 0.000 description 8
- 101000614013 Homo sapiens Lysine-specific demethylase 2B Proteins 0.000 description 8
- 101000613629 Homo sapiens Lysine-specific demethylase 4B Proteins 0.000 description 8
- 101001088892 Homo sapiens Lysine-specific demethylase 5A Proteins 0.000 description 8
- 101001088883 Homo sapiens Lysine-specific demethylase 5B Proteins 0.000 description 8
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 8
- 101001088879 Homo sapiens Lysine-specific demethylase 5D Proteins 0.000 description 8
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 description 8
- 101001008816 Homo sapiens N-lysine methyltransferase KMT5A Proteins 0.000 description 8
- 101000754924 Homo sapiens Ribosomal oxygenase 1 Proteins 0.000 description 8
- 102100040598 Lysine-specific demethylase 2A Human genes 0.000 description 8
- 102100040584 Lysine-specific demethylase 2B Human genes 0.000 description 8
- 102100040860 Lysine-specific demethylase 4B Human genes 0.000 description 8
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 8
- 102100033247 Lysine-specific demethylase 5B Human genes 0.000 description 8
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 8
- 102100033143 Lysine-specific demethylase 5D Human genes 0.000 description 8
- 101710096379 Lysine-specific histone demethylase 1 Proteins 0.000 description 8
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 229940124160 Myc inhibitor Drugs 0.000 description 8
- 101710150912 Myc protein Proteins 0.000 description 8
- 102100027771 N-lysine methyltransferase KMT5A Human genes 0.000 description 8
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 8
- 102100022091 Ribosomal oxygenase 1 Human genes 0.000 description 8
- 108091005770 SIRT3 Proteins 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 102220079741 rs797045487 Human genes 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- 208000019693 Lung disease Diseases 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 150000004713 phosphodiesters Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 6
- 102100033636 Histone H3.2 Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000006911 nucleation Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 101150022024 MYCN gene Proteins 0.000 description 4
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 4
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 238000011374 additional therapy Methods 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101150061166 tetR gene Proteins 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000003584 silencer Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000016261 weight loss Diseases 0.000 description 3
- 239000012130 whole-cell lysate Substances 0.000 description 3
- RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 2
- RKSLVDIXBGWPIS-UAKXSSHOSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 RKSLVDIXBGWPIS-UAKXSSHOSA-N 0.000 description 2
- QLOCVMVCRJOTTM-TURQNECASA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-TURQNECASA-N 0.000 description 2
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 2
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 2
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- LMMLLWZHCKCFQA-UGKPPGOTSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C#CC)O[C@H](CO)[C@@H](O)[C@H]1O LMMLLWZHCKCFQA-UGKPPGOTSA-N 0.000 description 2
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 2
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 2
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 2
- UEHOMUNTZPIBIL-UUOKFMHZSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7h-purin-8-one Chemical compound O=C1NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UEHOMUNTZPIBIL-UUOKFMHZSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101150084935 PTER gene Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101800001494 Protease 2A Proteins 0.000 description 2
- 101800001066 Protein 2A Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 102000051614 SET domains Human genes 0.000 description 2
- 108700039010 SET domains Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 102100031142 Transcriptional repressor protein YY1 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 108010045512 cohesins Proteins 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 239000002667 nucleating agent Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100058320 Arabidopsis thaliana BHLH12 gene Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 101100459256 Cyprinus carpio myca gene Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100033840 General transcription factor IIF subunit 1 Human genes 0.000 description 1
- 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 1
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 1
- 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 1
- 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 1
- 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101100293199 Mus musculus Myc gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 230000014632 RNA localization Effects 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101100459257 Solanum lycopersicum MYC1 gene Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102100040296 TATA-box-binding protein Human genes 0.000 description 1
- 108010083262 Transcription Factor TFIIA Proteins 0.000 description 1
- 102000006289 Transcription Factor TFIIA Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108091008820 oncogenic transcription factors Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010110 radioembolization Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000009199 stereotactic radiation therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000010741 sumoylation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108010014677 transcription factor TFIIE Proteins 0.000 description 1
- 108010014678 transcription factor TFIIF Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125833P | 2020-12-15 | 2020-12-15 | |
| US63/125,833 | 2020-12-15 | ||
| US202163137097P | 2021-01-13 | 2021-01-13 | |
| US63/137,097 | 2021-01-13 | ||
| US202163212991P | 2021-06-21 | 2021-06-21 | |
| US63/212,991 | 2021-06-21 | ||
| US202163281022P | 2021-11-18 | 2021-11-18 | |
| US63/281,022 | 2021-11-18 | ||
| PCT/US2021/010059 WO2022132195A2 (en) | 2020-12-15 | 2021-12-15 | Compositions and methods for modulation myc expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230120138A true KR20230120138A (ko) | 2023-08-16 |
Family
ID=82060102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237024060A Pending KR20230120138A (ko) | 2020-12-15 | 2021-12-15 | Myc 발현을 조절하기 위한 조성물 및 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240132559A1 (https=) |
| EP (1) | EP4262849A4 (https=) |
| JP (1) | JP2023553490A (https=) |
| KR (1) | KR20230120138A (https=) |
| AU (1) | AU2021401231A1 (https=) |
| CA (1) | CA3205133A1 (https=) |
| MX (1) | MX2023007116A (https=) |
| WO (1) | WO2022132195A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7682604B2 (ja) | 2016-09-07 | 2025-05-26 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | 遺伝子発現をモジュレートするための方法および組成物 |
| CN115192714B (zh) * | 2022-07-08 | 2024-09-17 | 沈阳药科大学 | Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| WO2024238726A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating methylation of a target gene |
| WO2024243438A2 (en) * | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025144907A1 (en) * | 2023-12-27 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Kinase inhibitors and particles comprising myc modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011972A1 (en) * | 1995-09-28 | 1997-04-03 | The Trustees Of Columbia University In The City Of New York | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| GB201119904D0 (en) * | 2011-11-17 | 2011-12-28 | Univ Vilnius | Analysis of methylation sites |
| US20170369855A1 (en) * | 2014-12-24 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Systems and methods for genome modification and regulation |
| KR101900278B1 (ko) * | 2016-04-18 | 2018-09-19 | 건국대학교 글로컬산학협력단 | Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법 |
| WO2018111944A1 (en) * | 2016-12-12 | 2018-06-21 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| JP2020515258A (ja) * | 2017-03-31 | 2020-05-28 | アジェノビア コーポレーション | 抗ウイルス治療剤 |
| US20190233805A1 (en) * | 2017-10-04 | 2019-08-01 | The Regents Of The University Of California | Targetable proteins for epigenetic modification and methods for use thereof |
| US20220380760A1 (en) * | 2018-10-15 | 2022-12-01 | Flagship Pioneering Innovations V, Inc. | Disrupting genomic complex assembly in fusion genes |
| US11866469B2 (en) * | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
-
2021
- 2021-12-15 KR KR1020237024060A patent/KR20230120138A/ko active Pending
- 2021-12-15 MX MX2023007116A patent/MX2023007116A/es unknown
- 2021-12-15 EP EP21907332.7A patent/EP4262849A4/en active Pending
- 2021-12-15 US US18/257,483 patent/US20240132559A1/en active Pending
- 2021-12-15 CA CA3205133A patent/CA3205133A1/en active Pending
- 2021-12-15 JP JP2023536049A patent/JP2023553490A/ja active Pending
- 2021-12-15 AU AU2021401231A patent/AU2021401231A1/en active Pending
- 2021-12-15 WO PCT/US2021/010059 patent/WO2022132195A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4262849A2 (en) | 2023-10-25 |
| EP4262849A4 (en) | 2024-10-30 |
| MX2023007116A (es) | 2024-01-08 |
| JP2023553490A (ja) | 2023-12-21 |
| CA3205133A1 (en) | 2022-06-23 |
| US20240132559A1 (en) | 2024-04-25 |
| WO2022132195A3 (en) | 2022-07-28 |
| WO2022132195A8 (en) | 2023-06-22 |
| WO2022132195A2 (en) | 2022-06-23 |
| AU2021401231A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230120138A (ko) | Myc 발현을 조절하기 위한 조성물 및 방법 | |
| JP7008850B2 (ja) | 核酸ターゲティング核酸の組成物および方法 | |
| KR20230074525A (ko) | 유전자 발현을 억제하기 위한 조성물 및 방법 | |
| KR102302679B1 (ko) | 가이드 rna 및 엔도뉴클레아제를 유효성분으로 포함하는 암 치료용 약학적 조성물 | |
| US12404557B2 (en) | Biomarkers predictive of anti-immune checkpoint response | |
| WO2020081598A1 (en) | Disrupting genomic complex assembly in fusion genes | |
| WO2020081588A1 (en) | Swi/snf family chromatin remodeling complexes and uses thereof | |
| KR20250068590A (ko) | Myc 발현을 조절하기 위한 제형 | |
| JP2025169372A (ja) | フラタキシン発現を調節し、フリードライヒ運動失調症を治療するための方法及び組成物 | |
| JP2011254830A (ja) | 結腸癌に関するポリヌクレオチド | |
| KR20230079181A (ko) | 다중 유전자의 발현을 억제하는 조성물 및 방법 | |
| US20220267756A1 (en) | Compositions and methods for modulating genomic complex integrity index | |
| WO2024040229A2 (en) | Combination therapies comprising myc modulators and checkpoint inhibitors | |
| TW202317601A (zh) | 用於調節ｍｙｃ表現之組合物及方法 | |
| WO2002101076A2 (en) | Methods for targeted expression of therapeutic nucleic acid | |
| WO2025019742A1 (en) | Methods and compositions for modulating ctnnb1 expression | |
| WO2025235563A1 (en) | Epigenetic modulation for upregulation of genes | |
| WO2024238723A1 (en) | Methods and compositions for modulating pcsk9 expression | |
| WO2025064469A1 (en) | Methods for assessing dosage for epigenetic modifying agents | |
| CN116635086A (zh) | 用于抑制多个基因的表达的组合物和方法 | |
| EP4713027A1 (en) | Methods and compositions for modulating methylation of a target gene | |
| CN116829175A (zh) | 用于调节myc表达的组合物和方法 | |
| HK1220734B (en) | Dna-guided dna interference by a prokaryotic argonaute |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230714 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241213 Comment text: Request for Examination of Application |